Fuest M, Yam G Hin-Fai, Peh G Swee-Lim, Walter P, Plange N, Mehta J S
Klinik für Augenheilkunde, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.
Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapur, Singapur.
Ophthalmologe. 2017 Aug;114(8):705-715. doi: 10.1007/s00347-017-0454-6.
In recent years, the cultivation and expansion of primary corneal cells has made significant progress. The transplantation of cultured limbal epithelial cells represents a successful and established treatment of the ocular surface. Cultivated corneal endothelial cells are undergoing a clinical trial in Japan. Stromal keratocytes can now be expanded in vitro. A wide range of stem cell sources is being tested in vitro and animal models for their possible application in corneal cell therapy. This article gives an overview of recent advancements and prevailing limitations for the use of different cell sources in the therapy of corneal disease.
近年来,原代角膜细胞的培养与扩增取得了显著进展。培养的角膜缘上皮细胞移植是一种成功且成熟的眼表治疗方法。培养的角膜内皮细胞正在日本进行临床试验。基质角膜细胞现在可以在体外扩增。多种干细胞来源正在体外和动物模型中进行测试,以评估它们在角膜细胞治疗中的潜在应用。本文概述了在角膜疾病治疗中使用不同细胞来源的最新进展和当前存在的局限性。